IP Library Granted Patent US 10,207,122
Granted Patent B2
US 10,207,122 · App. 14/687,716 · Granted Feb 19, 2019

Method and apparatus for electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans

Inventor: Arthur A. Pilla (Oakland, NJ)
Assignee: Endonovo Therapeutics, Inc.
A61N2/02A01G7/04A61N1/40A61N2/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,207,122
App. No.
14/687,716
Granted
Feb 19, 2019
Kind
B2
Abstract

Apparatus and methods for delivering electromagnetic signals configured specifically to accelerate the asymmetrical kinetics of the binding of intracellular ions to their respective intracellular buffers, to enhance the biochemical signaling pathways plant animal and human molecules, cells, tissues, organs, portions of entire organisms and entire organisms employ for growth, repair and maintenance. Described herein are devices and methods that utilize repetitive bursts of waveforms configured to maximize the bound concentration of intracellular ions at their associated molecular buffers to enhance the biochemical signaling pathways living systems employ for growth, repair and maintenance. For example the systems and methods described herein may drive the binding of calcium to calmodulin (CaM), thereby enhancing the CaM-dependent nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway.

Claims (33)

1. A method for electromagnetic treatment of plants, animals, and humans by accelerating ion binding to a corresponding molecule in a target pathway, the target pathway operating at a voltage, to modulate activity of biochemical signaling pathways plants, animals and humans employ for tissue growth, repair and maintenance, the method comprising:

activating an electromagnetic treatment device to treat the target pathway by inducing an electric field waveform having a pulse duration, random signal duration or carrier period which is less than twice an ion bound time to increase the voltage in the target pathway so as to accelerate ion binding of the ion to the corresponding molecule thereby modulating the target pathway,

wherein the step of activating comprises applying an electromagnetic signal to a capacitively coupled electrode applicator.

2. A method for electromagnetic treatment of plants, animals, and humans by accelerating ion binding to a corresponding molecule in a target pathway, the target pathway operating at a voltage, to modulate activity of biochemical signaling pathways plants, animals and humans employ for tissue growth, repair and maintenance, the method comprising:

activating an electromagnetic treatment device to treat the target pathway by applying an electromagnetic signal to a capacitively coupled electrode applicator thereby inducing an electric field waveform having a pulse duration, random signal duration or carrier period which is less than twice an ion bound time to increase the voltage in the target pathway so as to accelerate ion binding of the ion to the corresponding molecule thereby modulating the target pathway,

wherein the step of activating comprises applying an electromagnetic signal to a electrochemically coupled electrode applicator.

3. A method of treating a region of a patient's body to enhance calmodulin-dependent signaling pathways, the method comprising:

placing an electromagnetic treatment device on or over a region of the patient's body to be treated;

activating the electromagnetic treatment device to generate an electric field by applying an electromagnetic signal to a capacitively coupled electrode applicator having a pulse duration, random signal duration or carrier period which is less than twice a bound time of cytosolic calcium to calmodulin to accelerate calcium ion binding to calmodulin in the region of the patient's body.

4. The method of claim 3 , wherein the activating step further comprises generating an electric field comprising a 1 to 10 msec burst of a carrier frequency between 5 MHz to 50 MHz including the ISM band repeating between 1 and 10 bursts/sec and inducing a peak electric field less than 100 V/m.

5. The method of claim 4 , wherein the burst of carrier frequency further comprises one of: sinusoidal, rectangular, chaotic, or random wave shapes.

6. The method of claim 3 , wherein the placing step further comprises placing a coil applicator, electrode applicator, or coil and electrode applicator of the electromagnetic treatment device on or over the region of the patient's body to be treated.

7. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling, including NO/cGMP signaling to accelerate blood and lymph vessel dilation for relief of post-operative, post traumatic and musculoskeletal pain and edema.

8. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling, including NO/cGMP signaling to enhance angiogenesis and microvascularization for hard, soft or hard and soft tissue repair.

9. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling, including NO/cGMP signaling to enhance bone repair.

10. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling, including NO/cGMP signaling to enhance cartilage repair.

11. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling, including NO/cGMP signaling to reverse or prevent osteoporosis.

12. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling, including NO/cGMP signaling to accelerate deoxyribonucleic acid synthesis.

13. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling, including NO/cGMP signaling to modulate growth factor release.

14. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling, including NO/cGMP signaling to modulate cytokine production.

15. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling, including NO/cGMP signaling to accelerate the production of matrix proteins for tissue repair and maintenance.

16. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling, including NO/cGMP signaling to modulate cell and tissue differentiation.

17. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling pathways to prevent or reverse neurodegeneration.

18. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling to modulate heat shock protein release.

19. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling to modulate cognition and neuromuscular junction activity.

20. The method of claim 3 , further comprising generating an electric field having a pulse duration, random signal duration or carrier period to enhance CaM-dependent signaling to up regulate or down regulate messenger ribonucleic acid or gene expression associated with an enzyme, cytokine or growth factor employed for repair, growth and maintenance of tissue.

21. A method of treating a region of a patient's body to enhance calmodulin-dependent signaling pathways, the method comprising:

placing an electromagnetic treatment device on or over a region of the patient's body to be treated;

activating the electromagnetic treatment device to generate an electric field by applying an electromagnetic signal to a capacitvely coupled electrode applicator having a pulse duration, random signal duration or carrier period which is less than a bound time of cytosolic calcium to calmodulin to accelerate calcium ion binding to calmodulin in the region of the patient's body.

22. A method of applying a wearable electromagnetic treatment device to modulate the binding of calcium to calmodulin in a target tissue by applying electromagnetic waveforms to a tissue that match asymmetrical kinetic of binding of calcium to calmodulin, thereby enhancing calmodulin-dependent signaling, the method comprising:

positioning a wearable applicator of an electromagnetic treatment device adjacent to the target tissue; and

providing an electromagnetic signal to the applicator from the electromagnetic treatment device by applying an electrochemically coupled electrode applicator to induce an electric field of amplitude of less than about V/m at the target tissue and wherein the signal comprises a 1 to 10 msec burst of between 5 MHz and 50 MHz carrier waves including the ISM band, repeating at between 1 and 10 bursts/sec;

whereby calmodulin-dependent signaling is enhanced in the target tissue.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2024
From: ENDONOVO THERAPEUTICS, INC.
To: SOFPULSE, INC.
Reel/Frame 067933/0673 →
LICENSE Recorded Sep 24, 2019
From: RIO GRANDE NEUROSCIENCES, INC., ASSIGNOR TO ENDONOVO THERAPEUTICS INC.
To: AAH HOLDINGS LLC
Reel/Frame 050475/0809 →
SECURITY AGREEMENT Recorded Feb 1, 2018
From: ENDONOVO THERAPEUTICS, INC.
To: STEVEN M. GLUCKSTERN
Reel/Frame 045221/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2018
From: RIO GRANDE NEUROSCIENCES, INC.
To: ENDONOVO THERAPEUTICS INC.
Reel/Frame 044643/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2016
From: IVIVI HEALTH SCIENCES, LLC
To: RIO GRANDE NEUROSCIENCES, INC.
Reel/Frame 037445/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2015
From: IVIVI HEALTH SCIENCES, LLC
To: RIO GRANDE NEUROSCIENCES, INC.
Reel/Frame 037394/0244 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2015
From: PILLA, ARTHUR A.
To: IVIVI HEALTH SCIENCES, LLC
Reel/Frame 036332/0178 →
Continuity (23)
Division 13285761 · Oct 31, 2011
Continuation In Part 12819956 · Jun 21, 2010
Continuation In Part 12772002 · Apr 30, 2010
Continuation 11003108 · Dec 3, 2004
Continuation In Part 11114666 · Apr 26, 2005
Continuation In Part 11110000 · Apr 19, 2005
Continuation In Part 11369308 · Mar 6, 2006
Continuation In Part 11369309 · Mar 6, 2006
Continuation In Part 11223073 · Sep 10, 2005
Continuation In Part 11339204 · Jan 25, 2006
Continuation In Part 11818065 · Jun 12, 2007
Continuation In Part 11903294 · Sep 20, 2007
Continuation In Part 11977043 · Oct 22, 2007
Provisional Application 61456036 · Oct 29, 2010
Provisional Application 60527327 · Dec 5, 2003
Provisional Application 60564887 · Apr 26, 2004
Provisional Application 60563104 · Apr 19, 2004
Provisional Application 60568967 · Mar 7, 2005
Provisional Application 60568968 · Mar 7, 2005
Provisional Application 60812841 · Jun 12, 2006
Provisional Application 60846126 · Sep 20, 2006
Provisional Application 60852927 · Oct 20, 2006
Related Publication 20150217126A1 · Aug 6, 2015
Cited By (1)
US 12,702,854